摘要
目的:探索初治弥漫大B细胞淋巴瘤(DLBCL)患者病理组织中程序性死亡配体-1(PD-L1)与程序性死亡受体-1(PD-1)的表达情况。方法:收集2014年5月至2017年3月于北京大学第三医院血液内科就诊的DLBCL患者资料,选取现仍可获取初治时病理组织切片的患者21例。将患者依临床结局分为完全缓解及难治复发两组。采用多重荧光免疫组化染色的方法检测患者病理组织切片中PD-1、PD-L1表达情况及其表达比例,应用非参数检验比较不同分子标志物表达在不同临床特点组及不同预后组间的差异。结果:乳酸脱氢酶增高组患者PD-L1^(+)细胞与PD-1+细胞的比例(PD-L1^(+)∶PD-1+)为5.14±3.825,明显高于非增高组的0.76±0.563(P=0.001);Treg细胞增高组PD-L1^(+)∶PD-1+为1.41±1.454,明显低于减低组的6.42±4.426(P=0.023)。结论:初治DLBCL患者病理组织切片中PD-L1与PD-1的表达比例增高与不良预后临床特征相关。
Objective:To investigate the expression of PD-L1 and PD-1 in pathological tissue of patients newly diagnosed with diffuse large B-cell lymphoma(DLBCL).Methods:Data of DLBCL patients who visited the Department of Hematology,Peking University Third Hospital from May 2014 to March 2017 were collected,and a total of 21 patients with pathological tissue sections which were still available at the initial treatment were selected.The patients were divided into complete remission(CR)group and refractory relapse(RR)group according to clinical outcome.The expression and proportion of PD-1 and PD-L1 in pathological tissue sections were detected by multiplex fluorescence immunohistochemical staining,and the differences in the expression of different molecular markers in different clinical characteristics and different prognosis were compared using non-parametric test.Results:The ratio of PD-L1^(+)cells to PD-1+cells(PD-L1^(+):PD-1+)was 5.14±3.825 in increased lactate dehydrogenase(LDH)group,which was significantly higher than 0.76±0.563 in non-increased LDH group(P=0.001).The ratio of PD-L1^(+):PD-1+in increased Treg cells group was 1.41±1.454,which was lower than 6.42±4.426 in decreased Treg cells group(P=0.023).Conclusion:The increased expression ratio of PD-L1 to PD-1 in pathological tissue sections of newly diagnosed DLBCL patients is associated with poor prognostic clinical characteristics.
作者
包芳
克晓燕
BAO Fang;KE Xiao-Yan(Department of Hematology,Peking University Third Hospital,Beijing 100191,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2022年第3期778-783,共6页
Journal of Experimental Hematology
